References
- Abstracts of Papers Presented at the 4th Erfurt Conference on Platelets, held in June 1992 at the Medical Academy of Erfurt, Germany. Platelets 1993;4:49–60
- Anti-Platelet Therapy Group (including Heptinstall S). Collaborative overview of randomised trials of antiplatelet therapy prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994;308:81–100
- Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006;27:1038–1047
- Storey RF; Husted S, Harrington RA, Heptinstall S, Wilcox RG, Peters G, Wickens M, Emanuelsson H, Gurbel P, Grande P, et al. Inhibition of platelet aggregation by AZD6140, A reversible oral P2Y(12) receptor antagonist, compared with clopidogrel in patients with acute coronary syndrome. J Am Coll Cardiol 2007;50:1852–1856
- Dovlatova NL, Jakubowski JA, Sugidachi A, Heptinstall S. The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function. J Thromb Haemost 2008;6(7):1153–1159
- Groenewegen WA, Heptinstall S. A comparison of the effects of an extract of feverfew and parthenolide, a component of feverfew, on human platelet activity in vitro. J Pharm Pharmacol 1990;42:553–557
- Zhao L, Bath PMW, May J, Losche W, Heptinstall S. P-selectin, tissue factor and CD40 ligand expression on platelet–leucocyte conjugates in the presence of a GPIIb/IIIa antagonist. Platelets 2003;14:473–480
- Iyu D, Glenn JR, White AE, Johnson A, Heptinstall S, Fox S. The role of prostanoid receptors in mediating the effects of PGE3 on human platelet function. Thromb Haemost 2012;107:797–799
- Glenn JR, Dovlatova N, White AE, Dhillon K, Heptinstall S, Fox SC. VASPFix’ for measurement of VASP phosphorylation in platelets and for monitoring effects of P2Y12 antagonists. Thromb Haemost 2014;111:539–548
- Thomas MR, Wijeyeratne YD, May JA, Johnson A, Heptinstall S, Fox SC. A platelet P-selectin test predicts adverse cardiovascular events in patients with acute coronary syndromes treated with aspirin and clopidogrel. Platelets 2014;25:612–618